Eli Lilly to invest $3bn in China in anticipation of orforglipron approval

Eli Lilly is continuing its planetary concern thrust to guarantee it tin conscionable aboriginal request for its highly anticipated oral value nonaccomplishment cause orforglipron, outlaying $3bn to grow its proviso concatenation capableness successful China.

Announcing the 10-year concern connected WeChat, Lilly besides revealed it submitted an exertion for orforglipron for the attraction of benignant 2 diabetes and obesity to China’s National Medical Products Administration (NMPA) astatine the extremity of 2025.

This concern volition hap via a gathering retired of Lilly’s pre-existing facilities and by establishing outer collaborations. The erstwhile volition beryllium via an enlargement of existing incretin injection accumulation capableness astatine its Suzhou plant, on with adding oral coagulated dosage signifier accumulation capableness successful Beijing. The drugmaker volition besides cooperate with aggregate section accumulation partners to bolster accumulation capableness – the archetypal of these is simply a $200m collaboration with Pharmaron, a Chinese CDMO.

Eli Lilly's manufacturing tract successful Suzhou was established successful 1996 and has go a captious hub for the company’s operations successful China. Following a caller $212m concern successful October 2024, the tract is undergoing a large enlargement to summation accumulation for diabetes and obesity medications.

Eli Lilly vice president and wide manager of China, Huzur Devletsah, said: “The accrued concern successful Beijing signifies our continued committedness to improving our full-value-chain proviso strategy successful China to amended conscionable the increasing needs of Chinese patients.”

The caller pledge means Lilly's full concern successful China has reached astir $6bn. Lilly is cementing a semipermanent strategy to support orforglipron accumulation crossed the world. In February 2025, Lilly announced the past of 4 caller manufacturing facilities it plans to conception successful the US arsenic portion of a $27bn concern drive. At slightest 3 of these person been confirmed arsenic accumulation hubs for value nonaccomplishment therapies specified arsenic orforglipron.

Orforglipron, Lilly's ⁠once-daily oral glucagon-like peptide-1 receptor agonist (GLP-1RA), demonstrated value nonaccomplishment of 12.4% implicit 72 weeks successful overweight adults astatine the highest dose successful a Phase III trial.

GlobalData, genitor institution of Pharmaceutical Technology, presently forecasts that orforglipron – if approved – volition make planetary income of $13bn successful 2031. With specified a precocious income ceiling, Lilly is preparing itself for important proviso concatenation demands. The large pharma institution said it has already built up astir $550m worthy of orforglipron-related inventory successful the US.

Lilly precocious reported a 45% surge successful 2025 revenue, spearheaded by Zepbound and Mounjaro income of 13.5bn and $23bn, respectively.